<DOC>
	<DOCNO>NCT02662725</DOCNO>
	<brief_summary>This non-controlled , open label , Phase II Study ipilimumab combine Stereotactic Radiosurgery . The study include induction phase four IV infusion Ipilimumab 10 mg/kg every 3 week associate stereotactic radiosurgery perform 3 day 2nd ipilimumab administration . A Maintenance phase include Ipilimumab , IV , 10 mg/kg every 12 week , start week 24 , absence PD , unacceptable toxicity withdrawal consent disease progression . The primary objective overall survival . The Secondary objective include safety , ORR , PFS peripheral blood absolute lymphocyte count ( ALC ) predictive biomarker .</brief_summary>
	<brief_title>Ipilimumab Combined With Stereotactic Radiosurgery Melanoma Patients With Brain Metastases</brief_title>
	<detailed_description />
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Neoplasms , Second Primary</mesh_term>
	<mesh_term>Brain Neoplasms</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>1 . Willing able give write informed consent . 2 . Men woman ≥ 18 year age . 3 . Patient eligible single dose Stereotactic Radiotherapy ( Radiosurgery ) per pluridisciplinary committee . 4 . Neurologically asymptomatic paucisymptomatic patient . Patients moderate neurological symptom without systemic corticosteroid treatment include . 5 . Less 4 brain metastasis MRI . Brain metastasis measure le 3 cm diameter . At least one brain metastasis &gt; 5mm . 6 . Maximum one prior systemic therapy metastatic disease allow . 7 . Prior treatment INTERFERON adjuvant set authorize . Prior treatment antiCTLA4 NOT authorize . 8 . ECOG Performance Status 0 1 9 . Within last 2 week prior study day 1 follow laboratory parameter , within range specify : 1 . The patient require concomitant chronic treatment systemic corticosteroid immunosuppressive agent 7 day prior inclusion . 2 . Neurological symptom treat systemic corticosteroid ( whatever dose corticoid ) . 3 . The patient concurrent severe medical problem , unrelated malignancy , would significantly limit full compliance study expose patient unacceptable risk limit : Cardiac insufficiency ( III IV per NYHA classification ) , Renal insufficiency , ongoing infection . 4 . Any symptom concomitant tumour meningitis 5 . History immediate delay gadolinium hypersensitivity , contraindication undergo MRI examination ( Pacemaker , brain aneurysm clip ) 6 . Any concurrent malignancy nonmelanoma skin cancer , carcinoma situ cervix ( Subjects previous malignancy without evidence disease 5 year allow enter study ) 7 . Uncontrolled infectious disease require negative test clinically suspect HIV , HBV HCV . If positive result indicative true active chronic infection , subject may enter study discussion agreement Investigator Medical Monitor . 8 . Active autoimmune disease . Autoimmune disease : subject document history inflammatory bowel disease , include ulcerative colitis Crohn 's disease exclude study subject history symptomatic disease ( e.g. , rheumatoid arthritis , systemic progressive sclerosis [ scleroderma ] , Systemic Lupus Erythematosus , autoimmune vasculitis [ e.g. , Wegener 's Granulomatosis ] ) . 9 . Subjects motor neuropathy consider autoimmune origin ( e.g. , Guillain Barré Syndrome ) exclude study 10 . Previous treatment CTLA4 antagonist agent , include treatment adjuvant setting . 11 . The patient psychiatric addictive disorder may compromise his/her ability give inform consent comply trial procedure . 12 . Lack availability clinical followup assessment . 13 . For female patient : patient pregnant lactating . 14 . Women childbearing potential : refusal inability use effective mean contraception 15 . Participation another clinical trial protocol within 30 day prior enrolment 16 . Persons protect legal regime ( guardianship , trusteeship ) 17 . Patients emergency situation 18 . Patients keep detention</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>melanoma</keyword>
	<keyword>brain metastasis</keyword>
	<keyword>stereotactic radiosurgery</keyword>
	<keyword>Ipilimumab</keyword>
	<keyword>survival</keyword>
	<keyword>safety</keyword>
	<keyword>efficacy</keyword>
</DOC>